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Abstract: Maintenance chemotherapy has a long history of use in 
hematologic malignancies, in which the benefits are considerable in 
terms of survival and quality of life. Recently, several studies have 
demonstrated that maintenance therapy in non–small-cell lung can-
cer can prolong overall survival in patients who have benefited from 
initial platinum-based chemotherapy. These studies have led to regu-
latory approval of two agents (pemetrexed and erlotinib) in this set-
ting. We raise several issues regarding the design and execution of 
these studies, which question the validity of these conclusions, and 
explore aspects of the trial results concerning the optimal use of this 
approach, if it is to be accepted.
Key Words: Non–small-cell lung cancer, Chemotherapy, Duration, 
Maintenance.
(J Thorac Oncol. 2012;7: 1331–1336)
Maintenance therapies are generally used for chronic malignant diseases, that is, those diseases that may be 
controlled for years with long-term treatments. Maintenance 
treatment with low-dose chemotherapeutic agents to prevent 
disease recurrence once remission has been achieved is a clas-
sical approach (and terminology) used in various hematologic 
malignancies. Recently, an extensive body of research has 
emerged concerning maintenance therapy in advanced non–
small-cell lung cancer (NSCLC). In contrast to the situation 
in hematologic malignancy, the potential survival benefit is 
much more limited. Numerous reviews have been published 
in the past several years regarding this topic.1–5 Many of these 
articles include a variety of studies done over the past two 
decades. In fact, only a few recent studies using modern agents 
are truly relevant to the question. These trials break down into 
two approaches regarding maintenance (Table 1). First, the tri-
als that transition from a standard platinum doublet to a differ-
ent single agent (switch maintenance). Such trials are, in fact, 
about the optimal timing for introducing second-line therapy. 
Second, the trials that continue to administer the nonplatinum 
agent (continuation maintenance). Such trials are about the 
optimal duration of frontline therapy. Five randomized tri-
als have been reported that employ the switch-maintenance 
strategy, each with a different agent.6–11 The investigators logi-
cally chose agents that have demonstrated activity in patients 
who have progressed after prior platinum-containing ther-
apy.12–14 Three other trials have evaluated continuation main-
tenance.15–18 One of those studies evaluated both strategies.16 
Our article will not address the case of bevacizumab continu-
ation in NSCLC because this strategy has not been evaluated 
in a randomized setting.
There seems little doubt that continuation of chemother-
apy (either by changing to a new agent or by continuing with 
the nonplatinum portion of the initial regimen) will prolong 
progression-free survival (PFS) (Table 1). We believe that it 
is more important to determine whether this approach actu-
ally prolongs overall survival (OS) and/or the quality of life 
at an acceptable cost for patients and for society and is not an 
artifact of trial design or interpretation. We raise the following 
questions regarding these studies:
Is There a Fundamental Advantage  
for the Early Introduction of Additional Agents?
The initial impetus for the use of maintenance therapy 
was based upon mathematical and preclinical models indicat-
ing that the early introduction of additional agents would be 
of benefit.19,20 The basic theory is that the use of these agents 
at a time of lower tumor burden would be beneficial because 
there would be fewer clones of inherently resistant cells. If this 
hypothesis is correct, then there should be a survival advantage 
of the experimental (i.e., maintenance or early introduction) 
arm over the patients on the control (i.e., late introduction) 
arm that actually received the “study drug.” However, the 
weight of evidence is that this hypothesis has not been proved 
by these studies. The Fidias6 trial specifically reported the out-
comes of control patients who received docetaxel and showed 
no difference.
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Interestingly, no other study has reported the outcomes 
for control patients who either crossed-over to the “study 
agent” or to another acceptable drug. Unlike the situation 
with truly experimental drugs where there are questions 
regarding the benefits of a drug, most of the agents employed 
in these trials have been demonstrated to be active in patients 
who have progressed after treatment with platinum-based 
chemotherapy in prior randomized phase III trials, that is, 
pemetrexed and erlotinib. The exception is gemcitabine, 
which has demonstrated second-line activity in a multicenter 
phase II trial.21
Did the Control Group Perform Adequately?
This is perhaps the most significant and important 
issue with these trials. There are at least two major issues. 
First, did patients receive appropriate treatment upon dis-
ease progression? This is very questionable. To begin with, 
an unacceptably high number of patients failed to receive 
any therapy (Table 2). Depending upon the trial, this is up 
to 60% of patients. Proponents of maintenance will point to 
data that indicate that this is consistent with the overall use 
of second-line therapy. However, those figures apply to the 
overall lung cancer population, not to those who would have 
been randomized on this trial. It must be recalled that the 
requirement for randomization was that patients were stable 
or responding after four courses of platinum-based chemo-
therapy, had a PS 0 to 1, and had normal organ function. It is 
clear that where second-line therapy is mandated (e.g., the 
Intergroupe Français de Cancérologie Thoracique-Groupe 
Français de Pneumo-Cancérologie [IFCT-GFPC] study), at 
least 80% of the patients received second-line treatment. 
Furthermore, on the JMEN (pemetrexed maintenance) 
study, less than 20% of the patients received pemetrexed 
at the time of progression and only 50% received an appro-
priate agent (i.e., pemetrexed, docetaxel, epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitor [TKI] or 
research study) as second-line therapy. Similarly, in the 
Sequential Tarceva in Unresectable NSCLC (SATURN) 
trial, although 72% of the patients received some sort of 
second-line therapy, only 21% of the patients received erlo-
tinib. The other agents are reported only in broad classifi-
cations (e.g., antimetabolite or taxane) rather than as the 
specific agents. In an era in which second-line treatment 
TABLE 1. Trials of Maintenance Chemotherapy
Study Agent PFS (mo) OS (mo)
Switch 
maintenance
Fidias6 Docetaxel
Control
5.7*
2.7
12.3
9.7
JMEN Pemetrexed
Control
4.3*
2.6
13.4
10.6
SATURN Erlotonib
Control
2.8*
2.6
12.0*
11.0
ATLAS Erltonib
Control
4.8*
3.8
15.9
13.9
INFORM Gefitinib
Control
4.8*
2.6
18.7
16.9
Continuation 
maintenance
Belani15 Gemcitabine
Control
7.4
7.7
8.0
9.3
IFCT-GFPC 0502 Gemcitabine
Erlotinib
Control
3.8 *
2.9*
1.9
12.1
11.4
10.8
PARAMOUNT Pemetrexed
Control
3.9*
2.6
13.86*
11.1
*p < 0.05; PFS, progression-free survival; OS, overall survival; ATLAS, Phase 
IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and 
efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus 
bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC; 
INFORM, Iressa in Non-small cell for Maintenance; SATURN, Sequential Tarceva in 
Unresectable NSCLC; IFCT-GFPC, Intergroupe Français de Cancérologie Thoracique- 
Groupe Français de Pneumo-Cancérologie; PARAMOUNT, Phase III Study of 
Maintenance Pemetrexed (Pem) Plus Best Supportive Care (BSC) Versus Placebo Plus 
BSC Immediately Following Induction Treatment with Pem Plus Cisplatin for Advanced 
Nonsquamous Non-small Cell Lung Cancer. 
TABLE 2. Control Arm Therapy at Progression
Study Agent Crossover (%) Any Agent (%)
Fidias6 Docetaxel 62 62
JMEN Pemetrexed 18 67
SATURN Erlotonib 21 72
ATLAS Erlotinib 40 56
Belani15 Gemcitabine N/A* 17
IFCT-GFPC 0502 Gemcitabine
Erlotinib
N/A* 91
PARAMOUNT Pemetrexed N/A* 64
INFORM Gefitinib 30 (includes erlotinib) 67
*N/A not applicable, study of continuation maintenance, all patients received drug 
as part of induction.
ATLAS, Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the 
safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib 
versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic 
NSCLC; INFORM, Iressa in Non-small cell for Maintenance; SATURN, Sequential 
Tarceva in Unresectable NSCLC; IFCT-GFPC, Intergroupe Français de Cancérologie 
Thoracique-Groupe Français de Pneumo-Cancérologie; PARAMOUNT, Phase III Study 
of Maintenance Pemetrexed (Pem) Plus Best Supportive Care (BSC) Versus Placebo Plus 
BSC Immediately Following Induction Treatment with Pem Plus Cisplatin for Advanced 
Nonsquamous Non-small Cell Lung Cancer. 
TABLE 3. Benefits of Maintenance and Response Status
Study Agent Responder HR Stable Disease HR
Fidias6 Docetaxel 0.61* (OS) 1.02 (OS)
JMEN Pemetrexed 0.81 (OS) 0.61†(OS)
SATURN Erlotonib 0.94 (OS) 0.72† (OS)
ATLAS Erlotinib NR NR
Belani15 Gemcitabine NR NR
IFCT-GFPC 0502 Gemcitabine NR NR
PARAMOUNT Pemetrexed 0.48† (PFS) 0.74 (PFS)
INFORM Gefitinib NR NR
*p value not reported. 
†p < 0.05.2
OS, overall survival; PFS, progression-free survival; NR, not reported; HR, hazard 
ratio; ATLAS, Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the 
safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib 
versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic 
NSCLC; INFORM, Iressa in Non-small cell for Maintenance; SATURN, Sequential 
Tarceva in Unresectable NSCLC; IFCT-GFPC, Intergroupe Français de Cancérologie 
Thoracique-Groupe Français de Pneumo-Cancérologie; PARAMOUNT, Phase III Study 
of Maintenance Pemetrexed (Pem) Plus Best Supportive Care (BSC) Versus Placebo Plus 
BSC Immediately Following Induction Treatment with Pem Plus Cisplatin for Advanced 
Nonsquamous Non-small Cell Lung Cancer.
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has been clearly established, and established with specific 
drugs, it is simply not acceptable for studies that ask a 
question of early versus delayed therapy to fail to assure 
that patients are appropriately treated. In short, patients on 
the control arms received substandard care and therefore, 
the results are questionable.
If This Approach is Valid, Who 
Actually Benefits?
As one evaluates the data from these trials in greater 
depth, certain other patterns emerge. Most importantly, who 
actually benefits from maintenance? The SATURN (i.e., erlo-
tinib) study provides the clearest information. The popula-
tion that benefitted was patients with stable disease, with 
absolutely no benefit seen for those with actual responses. 
The European Medicines Agency felt that the indication for 
erlotinib in this setting should be restricted to patients with 
stable disease and not for those with response.22 Why is this 
important? It points to a fundamental problem with the defi-
nition of stable disease. Such patients can in fact have up to 
a 20% increase in the size of tumors and therefore in real-
ity have disease progression, though not meeting the formal 
definition.23 As demonstrated in Fig. 1, many stable patients 
may, in fact, be patients with early progression. Over the past 
few years, Waterfall plots have become a popular method of 
illustrating data as these graphs much more clearly indicate 
the actual status of patient response as opposed to the binary 
approach of response/stable versus progressive disease. A 
reasonable hypothesis is that the benefit seen from mainte-
nance in fact represents the early introduction of second-line 
therapy in a slowly progressing population of patients. This 
point is also fundamental when one contemplates the issue 
of why patients on the control arm were not treated. We will 
return to this issue shortly.
Another question, specifically relevant to the use of 
the EGFR TKIs, is whether patients who are EGFR wild-
type (wt) benefit. The two trials that have been reported with 
muational data (Iressa in Non-small cell for Maintenance 
[INFORM] and SATURN) clearly show marked PFS dif-
ferences for the TKI n patients with activating mutations 
(hazard ratio [HR] = 0.10 and median PFS of 16.6 months 
[versus 2.8 months] for INFORM and HR = 0.10 reported 
for SATURN). The third trial Phase IIIb, multicenter, ran-
domized, placebo-controlled trial to evaluate the safety 
and efficacy of chemotherapy+bevacizumab followed by 
bevacizumab+erlotinib versus bevacizumab+erlotinib pla-
cebo in subjects with locally advanced or metastatic NSCLC 
(ATLAS) has not been completely reported. Although 
there is a statistically significant benefit for wt patients, it 
is much less marked than that seen for mutated patients. In 
the INFORM trial, the HR is 0.86 with a median PFS of 2.7 
months versus 1.5 months (control) for wt patients; clearly, 
any benefit is minimal. The survival curves are essen-
tially identical. In the SATURN study, the HR is 0.78 and 
the median PFS or OS are not reported (visual inspection 
of the published curves reveals very modest differences). 
Furthermore, the OS results are not reported and because of 
the crossover effect, they are likely to be minimal. In sum-
mary, there is, at best, a slight advantage to maintenance 
EGFR TKIs in the EGFR wt population.
Why did Control Patients not 
Receive Second-Line Therapy?
Related to the issue that patients who benefit from sec-
ond line are those who are progressing but have not yet met 
the official definition of PD, is the timing of the introduction 
of therapy for those on the control arm. In most practices, 
an off-study patient would receive second-line treatment at 
the first indication of clinical or radiological progression. 
This might very well mean at a time when there is a 10% 
to 15% increase in tumor size as opposed to the Response 
Evaluation Criteria in Solid Tumours (RECIST) defined 20% 
increase or when there is a clinical but nonmeasurable pro-
gression. To the extent that patients do not receive treatment 
because “they fell off the cliff ”, i.e. progressed to such an 
extent that declining performance status, disease complica-
tions or death occurred suddenly, it may very well be a result 
of study design overcoming normal decision making. We 
have not been provided with any data regarding why patients 
on the control arm did not receive additional therapy. This 
issue is critical. The question of maintenance (and particu-
larly the switch maintenance approach) is not one of treat-
ment versus no treatment. Rather, it is a question of early 
versus late introduction of proven agents. Once again, the 
failure to assure that patients on the control arm received 
(or even had access to) the experimental agent is a serious 
design flaw.
Are Four Cycles of Platinum-Based 
Chemotherapy Truly Adequate?
All the maintenance trials have randomized patients 
after four courses of platinum-based therapy. This approach 
has been based upon a number of studies that indicated that 
most, if not all, benefit from initial chemotherapy occurred 
during the first four courses.24–26 These studies and analyses 
led to recommendations that patients with advanced NSCLC 
should be treated with four to six courses of platinum-based 
chemotherapy.27 However, it is still quite common in practice 
and part of several guidelines (American Society of Clinical 
Oncology, National Comprehensive Cancer Network) to 
employ six cycles of therapy, and further tumor shrinkage is 
frequently observed between the fourth and the sixth cycle of 
chemotherapy.28,29 There is no evidence to date that the use 
FIGURE 1. “Stable” disease is sometimes early progression.
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of maintenance after six courses of therapy is advantageous 
although the population able to tolerate six cycles is probably 
the population able to tolerate maintenance therapy. In other 
terms, the PFS benefit seen with maintenance trials in patients 
who have received four cycles of platinum-based therapy may 
be very similar and likely identical to the one obtained when 
continuing first-line doublets to six cycles.
Furthermore, one of the pivotal trials that form the 
basis of this recommendation for four cycles of chemo-
therapy is probably no longer relevant to this discussion. 
Socinski25 compared four cycles of carboplatin/paclitaxel 
with an indefinite number of cycles. The major limiting fac-
tor was cumulative neurotoxicity (19% at 4 cycles, 43% at 
8 cycles) due to paclitaxel. There was no difference in OS 
in this relatively small study (n = 230) though there was a 
numerical advantage for longer therapy (8.5 months ver-
sus 6.6 months, p = 0.63). In current practice, the use of 
pemetrexed-based regimens has supplanted taxane-based 
therapy for nonsquamous cancers. For squamous disease, 
gemcitabine-containing regimens offer comparable efficacy 
without the risk of neurotoxicity.
Which Study Might Answer the 
Question of Maintenance?
In fact, the real question in clinical practice is the strat-
egy of first-line chemotherapy for patients with advanced 
NSCLC and a good PS: Is it more appropriate to treat patients 
minimally, that is, with four to six cycles of a platinum doublet 
and offer a treatment holiday with close observation and rapid 
initiation of second-line therapy at the time of radiologic or 
symptom progression? Such a holiday offers freedom from 
treatment-related toxicity, inconvenience, and expense. Or 
is it better to treat them maximally, taking into account the 
tolerance of the treatment, clinical and radiological response, 
and the patient’s preference? This approach has almost invari-
ably been associated with a PFS benefit. For patients receiv-
ing switch maintenance it assures exposure to the second-line 
treatment.
To answer these questions, we need appropriately 
designed studies to properly assess these strategies and to 
determine whether there are specific populations of patients 
who might benefit. There must be a clear assessment of both 
the risks (including financial risk) and benefits. Randomization 
should be performed before any therapy is started, and an 
evaluation of quality of life should be mandatory. All patients 
in the short-treatment arm should receive a preestablished 
second line as soon as they exhibit a clinical or radiologic 
progression. The determination of progression should be a 
clinical decision and not necessarily based upon RECIST (e.g., 
a patient with a 15% increase in measurable disease could 
have second-line therapy initiated without protocol deviation). 
As some patients will not proceed to second-line therapy, 
there must be clear documentation as to why this occurred. 
An economic analysis is also indicated. This analysis should 
be detailed and allow for extrapolation to different health care 
systems. In an era of growing concern about the financial costs 
of treatment to both the patient and overall health care system, 
it is important to evaluate whether the potential benefits of 
therapy are worthwhile. There is no question that the costs are 
substantial. The incremental costs for pemetrexed or erlotinib 
as maintenance therapy exceed the acceptability thresholds in 
some health care systems.30–33 A suggested design of what we 
believe would be an appropriate switch-maintenance trial is 
provided in Fig. 2.
The issue with continuation maintenance is more 
straightforward. As we have discussed, the issue is duration 
of therapy. For nonsquamous carcinoma, a simple comparison 
of six cycles of treatment with platinum/pemetrexed followed 
FIGURE 2.  Optimal design of a switch-maintenance trial. NSCLC, non–small-cell lung cancer; OS, overall survival; PD, progres-
sive disease.
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by observation versus four cycles of the same regimen fol-
lowed by maintenance pemetrexed with similar assessments 
as described above (i.e., quality of life, economic analysis, 
etc.) is the simplest design. A third arm, evaluating continua-
tion of pemetrexed after six courses of the doublet could also 
be considered.
What should be the endpoints for such trials? PFS is 
frequently employed as it allows for a faster time to event and 
therefore a shorter study. Furthermore, it is uncontaminated by 
subsequent therapies.34 However, it is clearly inexact and sub-
jective.35 Prolongation of PFS has not always been associated 
with improvement of OS in lung cancer.36 Realistically, the 
prolongation of time to event for OS versus PFS is unfortu-
nately not all that long in advanced NSCLC. OS is an unequiv-
ocal and definitive endpoint suitable for drug appproval.37 In 
addition, for the question of maintenance, and in particular, 
for switch maintenance, the issue of subsequent therapy is 
not truly relevant as the agents in question have already been 
established as effective and the question is whether there is 
actually a benefit to an earlier introduction of that agent.
CONCLUSIONS
Maintenance treatment subjects patients to the continu-
ous toxicity and expense of chemotherapy. Quality-of-life 
analysis has not demonstrated even minimal benefit for either 
of the two strategies; a surprising finding, given the com-
mon assumption that delay of progression should result in 
improved quality of life.8,17,38 The randomized trials purporting 
to show advantages for the use of switch-maintenance peme-
trexed failed to provide the agent to patients randomized to 
the control arm, resulting in relatively few patients receiving 
the drug or an acceptable alternative. The question of switch-
maintenance therapy is not one of treatment versus no treat-
ment but rather of the early versus late introduction of a drug 
known to improve outcome. Despite statements by proponents 
that many patients on the control arm are unable to receive 
subsequent treatment, no data have been provided to support 
this position. For erlotinib, it is clear that virtually all benefit 
accrues to patients with activating EGFR mutations. There is 
little evidence to support the routine use of erlotinib as main-
tenance in patients without mutation and no evidence to sup-
port its use in patients who had response to initial treatment.
In summary, we believe that the issues discussed 
above raise serious questions regarding the adoption of 
switch-maintenance therapy for the routine treatment of all 
advanced NSCLCs. The issue of continuation maintenance 
is different and is really a question of the optimal dura-
tion of therapy. The recent results of the Phase III Study of 
Maintenance Pemetrexed (Pem) Plus Best Supportive Care 
(BSC) Versus Placebo Plus BSC Immediately Following 
Induction Treatment with Pem Plus Cisplatin for Advanced 
Nonsquamous Non-small Cell Lung Cancer (PARAMOUNT) 
study indicate that four cycles of platinum-based chemother-
apy are likely insufficient for optimal benefit. Reexamination 
of the basis of that recommendation demonstrates that much 
of the evidence basis results from the cumulative toxicity of 
taxane therapy. Pemetrexed/cisplatin reduces the potential for 
neurotoxicity while the use of pemetrexed/carboplatin would 
essentially eliminate the potential for neurotoxicity (albeit 
with a possible reduction in efficacy compared with cisplatin) 
compared with a taxane based regimen. Current recommen-
dations are for four to six cycles of treatment, and it seems 
that the greater number is optimal. It is unclear whether the 
benefits of indefinite continuation of maintenance therapy will 
be equal or superior to the benefits of six cycles of a platinum 
doublet. Practitioners must recognize that regulatory-agency 
approval of a drug for an indication does not mandate its use. 
This has been recognized in several guidelines that indicate 
that maintenance is an option, not a standard of care for all 
patients. It may very well be that selective use of maintenance 
in a subset of patients will be beneficial and appropriate. Only 
appropriately designed and independently conducted random-
ized studies can answer these questions.
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